Board President Tracy Smith is pleased and excited to introduce Will Staub as the new director of the library.
Zacks.com on MSN16h
Gilead Sciences (GILD) Rises As Market Takes a Dip: Key FactsGilead Sciences (GILD) ended the recent trading session at $85.83, demonstrating a +0.91% swing from the preceding day's closing price. This move outpaced the S&P 500's daily loss of 0.76%. Meanwhile, ...
The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To ...
On Friday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $84.95 which represents a slight increase of $0.28 or 0.33% from the prior close of $84.67. The stock opened at $84 ...
Shares of Gilead Sciences Inc. GILD inched 0.33% higher to $84.95 Friday, on what proved to be an all-around great trading ...
Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target ...
In a year that has seen an approval and a raft of readouts for metabolic dysfunction-associated steatohepatitis (MASH), ...
Gilead Sciences Inc. terminated a potential $785 million licensing deal with Yuhan Corp. inked in 2019 to develop metabolic dysfunction-associated steatohepatitis (MASH) therapies.
We recently made a list of Goldman Sachs’ List Of Stocks Popular With Mutual Fund Managers: Top 20 Stocks. In this piece, we ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback